Dr Shepherd has over 30 years’ experience in the pharmaceutical industry including CEO and executive business development roles around the globe. He has led multiple pharmaceutical asset and technology licensing transactions and has been responsible for strategic company-building acquisitions. He has also raised significant amounts of equity capital to build early stage companies into sustainable commercial operations.
He was previously CEO of CXR Biosciences and Neurotech S.A. in Europe and Vice President Business Development at ICN Pharmaceuticals Inc. and Intrabiotics Pharmaceuticals Inc. in the USA.
Andrew Sandham, Chairman & CEO, said “Tom is an accomplished business executive with substantial operating and transaction experience in the US, Europe and Japan. We are pleased to have attracted him to the Kymab team, as we launch our partnering programme.”
Tom Shepherd, CBO, said, “This is an exciting time to be joining the accomplished Kymab team in Cambridge, with a potentially world beating antibody generation platform just entering the partnering phase. “
About Kymab
Kymab was founded in 2009 based on research in the field of human immunology and mouse biology at the Wellcome Trust Sanger Institute in the laboratory of Professor Allan Bradley. The company is using embryonic stem cell technology to develop its Kymouse™ platform, which encompasses the entire diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond normal human immune response. The Kymouse™ will be used by Kymab for the discovery, development and commercialisation of antibody-based medicines. The platform will also be accessible through strategic alliances with pharmaceutical companies and academic institutions.
Contact:
Kymab Ltd
Andrew Sandham, Chairman & CEO
andrew.sandham@kymab.com,
+44 (0)1223 833301
